Triiodothyronine + baicalein

Triiodothyronine + baicalein has been studied in 1 paper since 2025: none in people yet, 1 in animals. The research so far is in animals. The newest paper, May 26, 2025: “Bidirectional upregulation of Klotho by triiodothyronine and baicalein: mitigating chronic kidney disease and associated complications in aged BALB/c mice”.

Intervention

1 paper studies it5 findingsUpdated

PubChemPubChemChEBIChEBI

See all 1 papers on triiodothyronine + baicalein

At a glance

The findings reach mice, none yet in people. 1 lab in 1 country.

None of its findings points the other way.

Mice: a single group. Cells, worms or flies and humans: nothing yet.
  • 1 lab in 1 country
  • Funders: Anusandhan National Research Foundation and 3 more
  • Animals1

What did studies of triiodothyronine + baicalein find?

5

Studies of triiodothyronine + baicalein measured 5 outcomes, among them dyslipidemia, cardiovascular disease and renal fibrosis.

Dyslipidemia

downin mice1

1 study
  1. Triiodothyronine + baicalein decreases dyslipidemia in mice (combined treatment in adenine-induced CKD mice).

    “mitigating renal fibrosis and CKD complications, including cardiovascular disorders and dyslipidemia”

    Animalscombined treatment in adenine-induced CKD mice

    Bidirectional upregulation of Klotho by triiodothyronine and baicalein: mitigating chronic kidney disease and associated complications in aged BALB/c mice

    Biogerontology

More on Dyslipidemia

Cardiovascular disease

downin mice1

1 study
  1. Triiodothyronine + baicalein decreases cardiovascular disease in mice (combined treatment in adenine-induced CKD mice).

    “mitigating renal fibrosis and CKD complications, including cardiovascular disorders and dyslipidemia”

    Animalscombined treatment in adenine-induced CKD mice

    Bidirectional upregulation of Klotho by triiodothyronine and baicalein: mitigating chronic kidney disease and associated complications in aged BALB/c mice

    Biogerontology

More on Cardiovascular disease

Renal fibrosis

downin mice1

1 study
  1. Triiodothyronine + baicalein decreases renal fibrosis in mice (combined treatment in adenine-induced CKD mice).

    “mitigating renal fibrosis and CKD complications, including cardiovascular disorders and dyslipidemia”

    Animalscombined treatment in adenine-induced CKD micekidney

    Bidirectional upregulation of Klotho by triiodothyronine and baicalein: mitigating chronic kidney disease and associated complications in aged BALB/c mice

    Biogerontology

TGF, NFκB and GSK3 signaling

downin mice1

1 study
  1. Triiodothyronine + baicalein decreases TGF, NFκB and GSK3 signaling in mice (combined treatment in adenine-induced CKD mice).

    “suppressed key signaling molecules (TGF, NFκB, GSK3)”

    Animalscombined treatment in adenine-induced CKD mice

    Bidirectional upregulation of Klotho by triiodothyronine and baicalein: mitigating chronic kidney disease and associated complications in aged BALB/c mice

    Biogerontology

Klotho

upin mice1

1 study
  1. Triiodothyronine + baicalein increases Klotho in mice (combined treatment in adenine-induced CKD mice) (surpassing individual effects of each agent).

    “Combined T3 and BAI treatment significantly increased Klotho levels, surpassing individual effects”

    Animalscombined treatment in adenine-induced CKD mice

    Bidirectional upregulation of Klotho by triiodothyronine and baicalein: mitigating chronic kidney disease and associated complications in aged BALB/c mice

    Biogerontology

More on Klotho

Latest